KR20140093726A - 디히드로피롤로[1,2-c]이미다졸릴 알도스테론 신타제 또는 아로마타제 억제제의 신규 형태 및 염 - Google Patents

디히드로피롤로[1,2-c]이미다졸릴 알도스테론 신타제 또는 아로마타제 억제제의 신규 형태 및 염 Download PDF

Info

Publication number
KR20140093726A
KR20140093726A KR1020147016954A KR20147016954A KR20140093726A KR 20140093726 A KR20140093726 A KR 20140093726A KR 1020147016954 A KR1020147016954 A KR 1020147016954A KR 20147016954 A KR20147016954 A KR 20147016954A KR 20140093726 A KR20140093726 A KR 20140093726A
Authority
KR
South Korea
Prior art keywords
salt
degrees
phosphate
phosphate salt
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147016954A
Other languages
English (en)
Korean (ko)
Inventor
폴 수튼
에릭 로에저
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47604250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20140093726(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20140093726A publication Critical patent/KR20140093726A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020147016954A 2012-01-17 2013-01-15 디히드로피롤로[1,2-c]이미다졸릴 알도스테론 신타제 또는 아로마타제 억제제의 신규 형태 및 염 Ceased KR20140093726A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261587280P 2012-01-17 2012-01-17
US61/587,280 2012-01-17
PCT/US2013/021521 WO2013109514A1 (en) 2012-01-17 2013-01-15 New forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR20147030158A Division KR20140141687A (ko) 2012-01-17 2013-01-15 디히드로피롤로[1,2-c]이미다졸릴 알도스테론 신타제 또는 아로마타제 억제제의 신규 형태 및 염

Publications (1)

Publication Number Publication Date
KR20140093726A true KR20140093726A (ko) 2014-07-28

Family

ID=47604250

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147016954A Ceased KR20140093726A (ko) 2012-01-17 2013-01-15 디히드로피롤로[1,2-c]이미다졸릴 알도스테론 신타제 또는 아로마타제 억제제의 신규 형태 및 염
KR20147030158A Ceased KR20140141687A (ko) 2012-01-17 2013-01-15 디히드로피롤로[1,2-c]이미다졸릴 알도스테론 신타제 또는 아로마타제 억제제의 신규 형태 및 염

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR20147030158A Ceased KR20140141687A (ko) 2012-01-17 2013-01-15 디히드로피롤로[1,2-c]이미다졸릴 알도스테론 신타제 또는 아로마타제 억제제의 신규 형태 및 염

Country Status (40)

Country Link
US (2) US9334276B2 (enExample)
EP (1) EP2804863B1 (enExample)
JP (1) JP5749410B2 (enExample)
KR (2) KR20140093726A (enExample)
CN (1) CN104039793B (enExample)
AP (1) AP2014007762A0 (enExample)
AR (1) AR089728A1 (enExample)
AU (1) AU2013209952B2 (enExample)
BR (1) BR112014017260A8 (enExample)
CA (1) CA2863339C (enExample)
CL (1) CL2014001863A1 (enExample)
CO (1) CO7000775A2 (enExample)
CR (1) CR20140345A (enExample)
CU (1) CU20140086A7 (enExample)
CY (1) CY1117914T1 (enExample)
DK (1) DK2804863T3 (enExample)
EA (1) EA026232B1 (enExample)
ES (1) ES2564143T3 (enExample)
GT (1) GT201400155A (enExample)
HR (1) HRP20160178T1 (enExample)
HU (1) HUE026984T2 (enExample)
IL (1) IL233541B (enExample)
IN (1) IN2014DN06781A (enExample)
JO (1) JO3137B1 (enExample)
MA (1) MA35858B1 (enExample)
MX (1) MX2014008686A (enExample)
NZ (1) NZ626277A (enExample)
PE (1) PE20142358A1 (enExample)
PH (1) PH12014501638A1 (enExample)
PL (1) PL2804863T3 (enExample)
RS (1) RS54589B1 (enExample)
SG (1) SG11201404061YA (enExample)
SI (1) SI2804863T1 (enExample)
SM (1) SMT201600083B (enExample)
TN (1) TN2014000256A1 (enExample)
TW (1) TWI609869B (enExample)
UA (1) UA114803C2 (enExample)
UY (1) UY34576A (enExample)
WO (1) WO2013109514A1 (enExample)
ZA (1) ZA201404314B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190071715A (ko) * 2016-10-27 2019-06-24 다미안 파르마 에이쥐 알도스테론 합성효소 저해제

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011205290C1 (en) * 2010-01-14 2014-11-06 Recordati Ag Use of an adrenal hormone-modifying agent
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
SI3166596T1 (sl) * 2014-07-07 2018-10-30 Novartis Ag Farmacevtske odmerne oblike
HUE054248T2 (hu) 2015-01-29 2021-08-30 Recordati Ag Eljárás kondenzált imidazo-származékok elõállítására
US20160287565A1 (en) * 2015-04-06 2016-10-06 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
WO2018078049A1 (en) * 2016-10-27 2018-05-03 Damian Pharma Ag Aldosterone synthase inhibitor
WO2019211394A1 (en) 2018-05-03 2019-11-07 Damian Pharma Ag R-fadrozole for use in the treatment of aldostonerism

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1315449A (en) * 1918-11-15 1919-09-09 Frank B Yingling Shaper-feed.
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US5066656A (en) 1989-11-01 1991-11-19 Janssen Pharmaceutica N.V. Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
MTP1076B (en) 1990-01-12 1991-09-30 Ciba Geigy Ag Hemihydrate
CA2127689A1 (en) 1992-01-27 1993-08-05 Marcel A. C. Janssen Pyrroloimidazolyl and imidazopyridinyl substituted 1h-benzimidazole derivatives as aromatase inhibitors
CA2505752A1 (en) 2002-11-18 2004-06-03 Novartis Ag Imidazo[1,5a]pyridine derivatives and methods for treating aldosterone mediated diseases
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
CN101578272A (zh) 2006-12-18 2009-11-11 诺瓦提斯公司 1-取代的咪唑衍生物和它们作为醛固酮合酶抑制剂的用途
US8575160B2 (en) 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
AU2011205290C1 (en) * 2010-01-14 2014-11-06 Recordati Ag Use of an adrenal hormone-modifying agent

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190071715A (ko) * 2016-10-27 2019-06-24 다미안 파르마 에이쥐 알도스테론 합성효소 저해제
KR20230037680A (ko) * 2016-10-27 2023-03-16 다미안 파르마 에이쥐 알도스테론 합성효소 저해제

Also Published As

Publication number Publication date
HRP20160178T1 (hr) 2016-03-25
TN2014000256A1 (en) 2015-09-30
JO3137B1 (ar) 2017-09-20
JP5749410B2 (ja) 2015-07-15
PH12014501638B1 (en) 2014-10-13
NZ626277A (en) 2015-10-30
CO7000775A2 (es) 2014-07-21
CU20140086A7 (es) 2014-12-26
IL233541A0 (en) 2014-08-31
IL233541B (en) 2018-12-31
PL2804863T3 (pl) 2016-06-30
RS54589B1 (sr) 2016-08-31
PE20142358A1 (es) 2015-01-30
BR112014017260A2 (pt) 2017-06-13
MX2014008686A (es) 2014-08-27
CR20140345A (es) 2014-09-09
TWI609869B (zh) 2018-01-01
EP2804863B1 (en) 2015-12-02
ES2564143T8 (es) 2020-11-18
US20140364470A1 (en) 2014-12-11
AU2013209952A1 (en) 2014-07-24
EP2804863A1 (en) 2014-11-26
JP2015503627A (ja) 2015-02-02
UA114803C2 (uk) 2017-08-10
ES2564143T3 (es) 2016-03-18
AU2013209952B2 (en) 2016-09-01
CL2014001863A1 (es) 2014-11-07
UY34576A (es) 2013-09-02
CY1117914T1 (el) 2017-05-17
SG11201404061YA (en) 2014-08-28
EA026232B1 (ru) 2017-03-31
AR089728A1 (es) 2014-09-10
US20160176883A1 (en) 2016-06-23
CA2863339C (en) 2021-03-23
SI2804863T1 (sl) 2016-05-31
GT201400155A (es) 2017-09-28
IN2014DN06781A (enExample) 2015-05-22
DK2804863T3 (en) 2016-03-07
US9334276B2 (en) 2016-05-10
EA201491374A1 (ru) 2014-12-30
PH12014501638A1 (en) 2014-10-13
ZA201404314B (en) 2015-08-26
CA2863339A1 (en) 2013-07-25
WO2013109514A1 (en) 2013-07-25
SMT201600083B (it) 2016-04-29
BR112014017260A8 (pt) 2017-07-04
CN104039793B (zh) 2017-05-10
HUE026984T2 (en) 2016-08-29
HK1198536A1 (en) 2015-05-15
AP2014007762A0 (en) 2014-07-31
KR20140141687A (ko) 2014-12-10
CN104039793A (zh) 2014-09-10
MA35858B1 (fr) 2014-12-01
TW201335161A (zh) 2013-09-01

Similar Documents

Publication Publication Date Title
KR20140141687A (ko) 디히드로피롤로[1,2-c]이미다졸릴 알도스테론 신타제 또는 아로마타제 억제제의 신규 형태 및 염
TWI433677B (zh) 雜環化合物及其用途
US8383608B2 (en) Imidazolidine compounds as androgen receptor modulators
US10131671B2 (en) Organic compounds
JP2010520292A (ja) 複素環式部分を含有するメタロプロテアーゼ阻害剤
KR20180137497A (ko) N-{6-(2-히드록시프로판-2-일)-2-[2-(메틸술포닐)에틸]-2h-인다졸-5-일}-6-(트리플루오로메틸)피리딘-2-카르복스아미드의 다형체 형태
CN103582478A (zh) 治疗神经退行性疾病的方法和组合物
JP6333996B2 (ja) がんを予防または治療するための、ブロモドメイン阻害化合物およびそれを含む医薬組成物
KR20190002468A (ko) N-[2-(3-히드록시-3-메틸부틸)-6-(2-히드록시프로판-2-일)-2h-인다졸-5-일]-6-(트리플루오로메틸)피리딘-2-카르복스아미드의 결정질 형태
CA2458131A1 (en) Jnk activation inhibitor
KR20200028436A (ko) Ask1 저해성 피롤로피리미딘 및 피롤로피리딘 유도체
CZ20032287A3 (cs) Způsoby léčení zánětlivých a imunitních nemocí za použití inhibitorů IkB kinázy (IKK)
CN112055590A (zh) 用于治疗醛固酮增多症的r-法屈唑
US20170217975A1 (en) Organic compounds
CA3194653A1 (en) Compositions and methods of treating kidney disease and fibrosis
TW201120043A (en) Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases
HK1198536B (en) New forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor
CN121735905A (zh) 氘代苯甲醇类trpv3抑制剂及其医药用途
JP2026515688A (ja) Aak1阻害剤としての窒素複素環系化合物
TW202615014A (zh) 作為蛋白質酪氨酸磷酸酶抑制劑的含雙鍵取代的化合物及其應用

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
PA0105 International application

Patent event date: 20140620

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140620

Comment text: Request for Examination of Application

A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20140623

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140826

Patent event code: PE09021S01D

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20141027

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150102

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140826

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20150102

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20141027

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20140620

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20150302

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150204

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20150102

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20141027

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20140826

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20140620

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20150401

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20150302

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20150102

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2015101001841

Request date: 20150401

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20160609

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20160609

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2015101001841

Request date: 20150401

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20160609

WITB Written withdrawal of application